Bromide

Bromide

SCHEMBL3316250

C=CC[N+](C)(CC=C)CCCCCCCCCCCC.[Br-]

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 10/20 0.50
TSHR P16473 2/20 0.48
ALDH1A1 P00352 1/20 0.48
TP53 P04637 1/20 0.48
CYP3A4 P08684 1/20 0.48
ALOX15 P16050 1/20 0.48
ALOX12 P18054 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HIF1A Q16665 1/20 0.48
HSD17B10 Q99714 1/20 0.48
HSP90AA1 P07900 1/20 0.46
RAD52 P43351 1/20 0.46
HTT P42858 2/20 0.46
SLC22A1 O15245 1/20 0.44
LSS P48449 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL7704309 1.00 DNM1 (0.50) DNM1TSHRALDH1A1TP53CYP3A4
Bromide SCHEMBL8853213 1.00 DNM1 (0.50) DNM1TSHRALDH1A1TP53CYP3A4
Bromide SCHEMBL28594641 1.00 DNM1 (0.50) DNM1TSHRALDH1A1TP53CYP3A4
Bromide SCHEMBL28597017 1.00 DNM1 (0.50) DNM1TSHRALDH1A1TP53CYP3A4
Bromide SCHEMBL11164888 1.00 DNM1 (0.50) DNM1TSHRALDH1A1TP53CYP3A4
Bromide SCHEMBL7901612 1.00 DNM1 (0.50) DNM1TSHRALDH1A1TP53CYP3A4
Bromide SCHEMBL5550538 1.00 DNM1 (0.50) DNM1TSHRALDH1A1TP53CYP3A4
Bromide SCHEMBL11169923 1.00 DNM1 (0.50) DNM1TSHRALDH1A1TP53CYP3A4
Bromide SCHEMBL22159436 1.00 DNM1 (0.50) DNM1TSHRALDH1A1TP53CYP3A4
Decane SCHEMBL7901634 0.98 DNM1 (0.48) DNM1TSHRALDH1A1TP53CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4348380-A CYCLOPOLYMERIZED SALT OF ALKYL DIALLYLAMINE L'OREAL (FR) 1982-09-07 US claimed
EP-2660252-A2 POLYSACCHARIDE-BASED GRAFT COPOLYMER AND COMPOSITION COMPRISING SAME FOR PERSONAL CARE Kci Limited (KR) 2013-11-06 EP disclosed
US-8562838-B2 Method for treating mineral sludge above ground using polymers SNF S.A.S. (FR) 2013-10-22 US disclosed
US-20130272989-A1 POLYSACCHARIDE-BASED GRAFT COPOLYMER AND COMPOSITION COMPRISING SAME FOR PERSONAL CARE KCI LIMITED (KR) 2013-10-17 US disclosed
US-7906567-B2 Process for producing encapsulated product, and encapsulated product SEIKO EPSON CORPORATION (JP) 2011-03-15 US disclosed
US-20100105976-A1 Method for treating mineral sludge above ground using polymers SNF S.A.S. (FR) 2010-04-29 US disclosed
US-20080039550-A1 Process for producing encapsulated product, and encapsulated product SEIKO EPSON CORPORATION 2008-02-14 US disclosed
US-20070190021-A1 Poly(diallylamine)-based bile acid sequestrants HOLMES-FARLEY STEPHEN R 2007-08-16 US disclosed
US-7125547-B2 Poly(diallylamine)-based bile acid sequestrants GENZYME CORPORATION (US) 2006-10-24 US disclosed
US-20040151687-A1 Poly(diallylamine)-based bile acid sequestrants GENZYME CORPORATION 2004-08-05 US disclosed
WO-1999022743-A1 POLY(DIALLYLAMINE)-BASED PHOSPHATE BINDERS GELTEX PHARMACEUTICALS, INC. (US) 1999-05-14 WO disclosed
WO-1998029107-A2 POLY(DIALLYLAMINE)-BASED BILE ACID SEQUESTRANTS GELTEX PHARMACEUTICALS, INC. (US) 1998-07-09 WO disclosed
US-5624570-A CLARIFICATION OF WASH WATER WITH POLYMER AND CATIONIC, NONIONIC OR ANIONIC ACRYLAMIDE POLYMER WITH DIMETHYL DALLYL AMMONIUM CHLORIDE CALGON CORPORATION (US) 1997-04-29 US disclosed
EP-0526800-A1 Polymers from N-containing monomers polymerised in the presence of monosaccharids, oligosaccharids or polysaccharids and derivatives BASF Aktiengesellschaft (DE) 1993-02-10 EP disclosed
US-5101047-A Sulfobetaine-substituted α-sulfonylcarboxylic acids from diallylammonium salts and a process for the preparation thereof BALLSCHUH DETLEF (DE) 1992-03-31 US disclosed
US-5099043-A 3-METHYLSULFONYLMETHYL-4-SULFOMETHYL-PYRROLIDINIUM-BETAINES AND PROCESS FOR THEIR PREPARATION BALLSCHUH DETLEF (DE) 1992-03-24 US disclosed
EP-0434175-A1 Sulphobetain-substituted alpha-sulphonyl carboxylic acids from diallylammonium salts and process for their preparation INSTITUT FÜR CHEMISCHE TECHNOLOGIE (DE) 1991-06-26 EP disclosed
EP-0434174-A1 3-Methylsulfonylmethyl-4-sulfomethyl-pyrrolidinium betains and process for their preparation INSTITUT FÜR CHEMISCHE TECHNOLOGIE (DE) 1991-06-26 EP disclosed
US-4410709-A Sulfobetaines AKADEMIE DER WISSENSCHAFTEN DER DDR (DD) 1983-10-18 US disclosed
US-4283384-A Cosmetic compositions containing polymers produced in the presence of cerium ions L'OREAL (FR) 1981-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070190021-A1 Poly(diallylamine)-based bile acid sequestrants NR1H4, SLC10A2, SLC10A1 DNM1 3581/4885TSHR 4075/4885ALDH1A1 2873/4885
US-20130272989-A1 POLYSACCHARIDE-BASED GRAFT COPOLYMER AND COMPOSITION COMPRISING SAME FOR PERSONAL CARE PHOSPHO1, ALG1, PHYKPL DNM1 4049/4885TSHR 4730/4885ALDH1A1 3090/4885
US-20040151687-A1 Poly(diallylamine)-based bile acid sequestrants NR1H4, SLC10A2, SLC10A1 DNM1 3469/4885TSHR 4388/4885ALDH1A1 2717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.